Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial
June 24 (Reuters) - Nektar Therapeutics NKTR.O said on Tuesday its experimental eczema drug had met the main goals of a mid-stage study.
Shares of the company were halted in premarket trading.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Precious Metals May Outlook: After U.S.-Iran Conflict Concerns Eased, Will Funds Flow Back to Gold and Silver?

Is SanDisk the Hidden Gem of the AI Boom in 2026? Discover the Potential Risks and Rewards.

Intel vs. TSM: Which Semiconductor Stock Looks Like the Better Investment?

What Is Intel, and Is Its Stock Still a Worthwhile Investment?

Amazon vs. Microsoft: Which Stock Is a Better Buy for 2026 and Beyond?

Tradingkey








